Table 2.

Global physician's assessment of disease status, disease location, and calprotectin levels of patients and volunteers and the percentage of IgG-coated bacteria with or without incubation with autologous serum

Identifiera	Global physician's assessment (in remission/active)	Disease location	Calprotectin amt (mg/kg)	% IgG-coated bacteria
				In vivo coating	In vivo + serum
P1	Active	Ileal/colonic	2,357	3.1	10.1
P2	Active	Ileal/colonic	2,140	19.8	17.0
P3	Active	Ileal/colonic	1,604	3.4	3.8
P4	Active	Ileal	1,091	0.7	1.7
P5	Active	Ileal/colonic	841	2.4	4.5
P6	Active	Ileal	273	2.0	4.4
P7	Active	Ileal	227	2.2	7.6
P8	Active	Ileal	215	1.5	12.2
P9	Active	Ileal/colonic	89	0.9	2.3
P10	Remission	Ileal/colonic	465	1.9	5.1
P11	Remission	Ileal	323	2.3	12.4
P12	Remission	Colonic	322	2.7	9.6
P13	Remission	Ileal	249	1.6	8.0
P14	Remission	Colonic	246	1.4	7.3
P15	Remission	Ileal	229	1.5	3.2
P16	Remission	Colonic	229	1.3	3.4
P17	Remission	Ileal	197	0.8	2.9
P18	Remission	Ileal/colonic	133	1.3	10.2
P19	Remission	Ileal	124	0.6	2.0
P20	Remission	Ileal/colonic	106	1.7	2.5
P21	Remission	Ileal/colonic	97	4.0	43.5
P22	Remission	Ileal/colonic	72	1.3	10.0
P23	Remission	Ileal/colonic	<20	3.0	10.1
Median (23 patients)			229	1.7	7.3
V1	NAb	NA	31	1.6	3.4
V2	NA	NA	24	0.7	1.6
V3	NA	NA	<20	0.4	1.7
V4	NA	NA	<20	1.8	3.3
V5	NA	NA	<20	1.4	3.9
V6	NA	NA	<20	1.7	3.1
V7	NA	NA	<20	1.3	3.5
V8	NA	NA	<20	1.3	2.6
V9	NA	NA	<20	1.1	2.6
V10	NA	NA	<20	2.6	19.8
V11	NA	NA	<20	1.3	1.5
Median (11 volunteers)			<20	1.3	3.1

^aP, patient; V, volunteer.

^bNA, not assessed.